Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
irinotecan liposome + sintilimab is a combination therapy being investigated for the treatment of advanced gastric cancer. It consists of a liposomal formulation of irinotecan, a topoisomerase I inhibitor, and sintilimab, a recombinant humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. The liposomal delivery system for irinotecan is designed to enhance the drug's half-life and tumor accumulation, where it is converted to its active metabolite SN-38 to induce DNA damage. Sintilimab acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to restore the anti-tumor activity of T cells. This specific combination is being evaluated in a Phase II clinical trial led by Ruijin Hospital as a second-line treatment for patients with progressive gastric cancer who have failed prior therapies.
- Brand names
- Tyvyt
- Other names
- Liposomal Irinotecan + SintilimabIrinotecan liposome injection II + Sintilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposome + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + sintilimab.